Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mapping Cancer's next move: study tracks where prostate cancer returns after aggressive radiotherapy

NCT ID NCT07686016

Knowledge-focused Sponsor: Affidea Nu-med Center of Oncological DIagnostics and Therapy Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study follows 700 men with prostate cancer that has spread to up to 10 spots in the body (oligometastatic). All receive radiotherapy to the prostate and to each visible metastasis, along with standard systemic therapy. Researchers collect real-world data from medical records to see where and when the cancer progresses after this comprehensive treatment. The goal is to understand patterns of failure and identify factors linked to better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radiotherapy
What this could lead to
If successful, this could help doctors better predict and manage prostate cancer that has spread to a few spots, potentially improving treatment plans.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove what treatment works best. Results may vary based on routine care differences.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 700 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with synchronous de novo oligometastatic prostate cancer, defined as metastatic prostate adenocarcinoma diagnosed at initial presentation or within 6 months of primary diagnosis, with up to 10 extraregional metastatic lesions. Patients are treated in routine clinical practice with definitive prostate-directed radiotherapy, which may include external-beam radiotherapy, brachytherapy boost, or definitive brachytherapy monotherapy, and metastasis-directed radiotherapy to all identified extraregional metastatic lesions.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed adenocarcinoma of the prostate. * Male sex. * Age 18 years or older. * Synchronous de novo metastatic prostate cancer diagnosed at initial presentation or within 6 months of primary prostate cancer diagnosis. * Up to 10 extraregional metastatic lesions on staging imaging used for clinical decision-making. * Treatment with definitive prostate-directed radiotherapy, including external-beam radiotherapy alone, external-beam radiotherapy with brachytherapy boost, or definitive prostate brachytherapy monotherapy in selected patients. * Treatment with SBRT or another ablative metastasis-directed radiotherapy approach to all identified extraregional metastatic lesions. * Availability of sufficient clinical, imaging, radiotherapy, systemic therapy, follow-up, adverse event, and survival data for outcome assessment. * For prospectively enrolled patients, ability to provide informed consent where required by local ethics and regulatory procedures. Exclusion Criteria: * More than 10 extraregional metastatic lesions at baseline staging. * Incomplete metastasis-directed therapy, defined as treatment of selected metastatic lesions only while leaving other known baseline extraregional metastatic sites untreated. * Prostate-directed radiotherapy delivered with palliative rather than definitive intent. * Missing key dates preventing outcome determination, including prostate-directed radiotherapy, brachytherapy, metastasis-directed SBRT dates, or follow-up information. * Prior definitive treatment of prostate cancer before diagnosis of synchronous metastatic disease. * Histology other than adenocarcinoma of the prostate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic prostate cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic prostate cancer Oligometastatic prostate cancer Prostate cancer Synchronous oligometastatic prostate cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affidea Nu-med Center of Oncological Diagnostics and Therapy

    RECRUITING

    Zamość, Lublin Voivodeship, 22-400, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.